WHO – Pharma.Tips

CAPA follow-up weak during FDA/EMA inspection – CAPA closure verification

Strengthening CAPA Follow-Up for Enhanced FDA/EMA Inspection Outcomes In pharmaceutical manufacturing and quality assurance, Corrective and Preventive Actions (CAPA) serve as the backbone of quality management systems (QMS). However, persistent…

Validation gaps identified during change control – inspection evidence expectations

Identifying and Addressing Validation Gaps During Change Control for Inspection Readiness Validation gaps occurring during change control represent a critical challenge for pharmaceutical manufacturers. When inadequacies arise in the validation…

Change impact not assessed during lifecycle management – regulatory deficiency risk

“`html Assessing Change Impact During Lifecycle Management to Mitigate Regulatory Risks In the highly regulated pharmaceutical industry, change management is pivotal to maintaining compliance with Good Manufacturing Practices (GMP). Neglecting…

Validation gaps identified during system upgrades – inspection evidence expectations

Playbook for Identifying and Addressing Validation Gaps During System Upgrades Validation gaps during system upgrades can pose significant risks to compliance within pharmaceutical manufacturing. These gaps not only jeopardize production…

Change impact not assessed during change control – inspection evidence expectations

Assessing Change Impact in Change Control: A Comprehensive Playbook for Compliance In pharmaceutical manufacturing, the rigorous process of change control is fundamental to maintaining compliance and ensuring product quality. However,…

Validation gaps identified during site expansion – regulatory deficiency risk

Addressing Validation Gaps Found During Facility Expansion to Mitigate Regulatory Deficiencies With the rapid growth of the pharmaceutical industry, site expansions often create numerous challenges, particularly concerning validation protocols. Regulatory…

Validation gaps identified during change control – regulatory deficiency risk

Addressing Validation Gaps During Change Control to Mitigate Regulatory Risks Validation gaps during change control can lead to substantial regulatory deficiencies, particularly under the scrutiny of compliance inspections by the…

Inadequate worst-case selection during change control – risk-based validation alignment

Addressing Inadequate Worst-case Selection During Change Control for Risk-based Validation In the ever-evolving landscape of pharmaceutical manufacturing, inadequate worst-case selection during change control presents significant regulatory risks. Insufficient analysis not…

Validation gaps identified during change control – preventing repeat validation findings

Addressing Validation Gaps in Change Control to Prevent Recurring Findings Validation gaps identified during change control can significantly hinder pharmaceutical manufacturing compliance and efficiency. When these gaps remain unaddressed, they…

Inadequate worst-case selection during lifecycle management – preventing repeat validation findings

“`html Mitigating Inadequate Worst-Case Selection in Lifecycle Management: A Practical Playbook Pharmaceutical manufacturing and quality control processes are complex and require meticulous attention to detail. One recurring issue is inadequate…

Inadequate worst-case selection during site expansion – CAPA and revalidation strategy

Addressing Inadequate Worst-Case Selection: A Playbook for Site Expansion CAPA and Revalidation In the fast-paced environment of pharmaceutical manufacturing, adequate planning and rigorous validation are essential, especially during site expansions.…

Requalification overdue during change control – CAPA and revalidation strategy

Managing Requalification Delays Amid Change Control – A Pragmatic CAPA Approach The pharmaceutical industry continually faces challenges related to maintaining compliance with Good Manufacturing Practices (GMP) and meeting regulatory expectations.…